LENG1: A Protein Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: LENG1

NCBI ID: G79165

LENG1

Other Name(s): Leukocyte receptor cluster (LRC) member 1 protein | leukocyte receptor cluster (LRC) member 1 | LENG1_HUMAN | Leukocyte receptor cluster member 1 | leukocyte receptor cluster member 1

LENG1: A Protein Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

LENG1, also known as Leukocyte receptor cluster member 1 protein, is a protein that is expressed in a variety of cell types, including white blood cells, nerve cells, and muscle cells. It is a member of the leukocyte receptor cluster (LRC), which is a protein family that is involved in the signaling of immune and inflammatory responses.

The LRC is a large family of proteins that are characterized by the presence of a nucleotide-binding oligomerization domain (NOD), which is a protein-coding region that is held together by a nucleotide. This domain is responsible for the protein's ability to interact with DNA and other nucleotides, as well as for its ability to regulate gene expression and other cellular processes.

LENG1 is a 21-kDa protein that is expressed in a variety of tissues and cells, including the brain, spinal cord, heart, kidneys, and gastrointestinal tract. It is primarily localized to the cytoplasm of these cells, where it is involved in the regulation of various cellular processes, including cell signaling, DNA replication, and protein synthesis.

One of the most interesting aspects of LENG1 is its potential as a drug target. LENG1 has been shown to be involved in the regulation of cellular processes that are important for the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, LENG1 has been shown to be involved in the regulation of cell signaling pathways that are important for the development of cancer. In many cancers, the signaling pathways that are responsible for regulating cell growth and division are disrupted, leading to the development of uncontrolled cell growth and the formation of tumors. LENG1 has been shown to be involved in the regulation of these signaling pathways, and it is possible that targeting LENG1 with drugs could be an effective way to treat some cancers.

LENG1 has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, and they are often associated with the development of other progressive neurodegenerative diseases. LENG1 has been shown to be involved in the regulation of the neurotransmitter systems that are responsible for transmitting signals between cells in the brain, and it is possible that targeting LENG1 with drugs could be an effective way to treat these conditions.

In addition to its potential as a drug target, LENG1 has also been shown to be involved in the regulation of other cellular processes that are important for the development and maintenance of health. For example, LENG1 has been shown to be involved in the regulation of cell signaling pathways that are important for the development and maintenance of the immune system, and it is possible that targeting LENG1 with drugs could be an effective way to treat autoimmune disorders.

Overall, LENG1 is a protein that has the potential to be a drug target for a variety of diseases. While more research is needed to fully understand the role of LENG1 in these processes, it is an promising area of research that has the potential to lead to new and effective treatments for a variety of conditions.

Protein Name: Leukocyte Receptor Cluster Member 1

The "LENG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LENG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets